Faculty

Gary Schiller, MD, FACP 

Dr. Schiller is the Director of the Hematological Malignancy/ Stem Cell Transplant Program at the David Geffen School of Medicine at UCLA, supervising 200 transplants per year.  He has extensive clinical research experience, having conducted many investigator-initiated and multicenter trials, mostly in Hematologic Malignancies as well as Blood and Marrow Transplantation.  He is immediate past Chair of the Faculty Executive Committee for the School of Medicine at UCLA. He is an author of over 220 publications and 450 abstracts and presented in more than 350 events. He has mentored residents, medical students, and fellows for more than 30 years.  He has also served as a member and Chair of the Committee on Training for the American Society of Hematology and worked with its Trainee Council developing programs for the national meeting of the Society and curriculum for its Trainee Day and is presently Chair of the ASH Foundation committee.

Dr. Schiller has an outstanding track record in clinical research, teaching, and mentoring and was co-investigator on Alternative Training grant for Bone Marrow Failure syndromes.  He also has extensive experience outside of medicine, with nonprofit, charitable institutions.  He has served on the Board of Trustees of Wilshire Boulevard Temple, and was Chairman of the Los Angeles Museum of the Holocaust. Dr. Schiller has 30 years of experience in the diagnosis and management of adults with Hematologic Malignancies and those undergoing allogeneic stem cell transplantation for non-malignant disorders including sickle cell disease.

Disclosures:

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous. 

All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.

Gary Schiller, MD FACP MD discloses contracted research with AbbVie, Actinium, Actuate, Agios, Arog, Astellas, Amgen, Aptevo, AltruBio, AVM Bio, BMS/ Celgene, Biopath, BioMea, Biosight, Cellularity, Celator, Constellation, Cogent, Cellectis, Daiichi-Sankyo, Deciphera, Delta-Fly, Fate, Forma, FujiFilm, Gamida, Genentech-Roche, Rigel Glycomimetics, Geron, Gilead, lncyte, Karyopharm, Kiadis, Kite/Gilead, Kronos Bio, Kura, Janssen, lmmunogene, Loxo, Marker, Mateen, Onconova, Pfizer, PrECOG, Regimmune, Samus, Sangamo, Sellas, Stemline, Syros, Takeda, Tolero, Trovagene, Agios, Amgen, Jazz, Orea, Ono-UK, Novartis, Cullinan, Consulting Fee’s with BMS, Curios and Daiichi Sankyo, Boxer Capital, Targeted Oncology, UJL Healthcare, Gather-ed, Med Exchange international, Acute Leukemia Forum, University of Maryland Speaker’s Bureau and Honoria with Agios, Jazz, Amgen, BMS Astellas, Seattle Genetics, Karyopharm, Rigel, Onlive and GSK. Advisory board with Axon Advisory, BMS and Stocks with Amgen, BMS and Janssen/J&J during the past 24 months.